Related Experiment Videos
[Pleading to maintain hydroxychloroquine throughout Lupus pregnancies]
N Costedoat-Chalumeau1, Z Amoura, D Le Thi Huong
1Service de médecine interne, CHU Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France. nathalie.costedoat@psl.ap-hop-paris.fr
La Revue De Medecine Interne
|June 7, 2005
Summary
Continuing Hydroxychloroquine (HCQ) during pregnancy is generally safe for patients with systemic lupus erythematosus (SLE). The benefits of maintaining HCQ outweigh potential risks, supporting its use throughout gestation and postpartum.
Area of Science:
- Rheumatology
- Maternal-Fetal Medicine
- Pharmacology
Context:
- Systemic lupus erythematosus (SLE) activity often increases during pregnancy.
- Discontinuing Hydroxychloroquine (HCQ) in pregnant SLE patients may lead to disease exacerbation.
- Pregnancy outcomes in SLE patients require careful management of immunosuppressive therapies.
Purpose:
- To evaluate the safety and efficacy of continuing Hydroxychloroquine (HCQ) during pregnancy for patients with SLE.
- To assess the risks and benefits of HCQ use in pregnant SLE patients compared to withdrawal.
- To provide evidence-based recommendations for HCQ management in SLE during gestation.
Summary:
- Available data indicate that Hydroxychloroquine (HCQ) can be safely continued throughout pregnancy in SLE patients.
- Over 250 pregnancies with HCQ use have resulted in live births without demonstrated increases in birth defects.
- No significant retinal or ototoxicity was observed in children exposed to HCQ in utero; lactation data suggest minimal exposure.
Impact:
- Continuing HCQ during pregnancy for SLE patients offers benefits that appear to exceed hypothetical risks.
- Maintaining HCQ treatment throughout pregnancy is recommended for SLE patients, with no contraindication for breastfeeding.
- Further prospective studies are needed to definitively confirm the long-term safety of in utero HCQ exposure.